<?xml version="1.0" encoding="UTF-8"?>
<p id="p0270">RDV therapy promising results are described for several viral infections. Regarding EBOV, primary evaluation includes evidence of its efficacy both 
 <italic>in-vitro</italic> (primary macrophage and human endothelial cells) and 
 <italic>in-vivo</italic> (rhesus monkey) by suppressing viral replication and completely protecting animals as clinical symptoms of the disease and pathophysiology markers improved.
 <xref rid="b0655" ref-type="bibr">
  <sup>131</sup>
 </xref> The safety of RDV for humans infected with EBOV was evaluated in the Democratic Republic of Congo. Results confirmed its safety but did not point RDV as the best therapeutic option, once its mortality rate reached 53% of treated group.
 <xref rid="b0660" ref-type="bibr">
  <sup>132</sup>
 </xref>
</p>
